Targeted pill trial aims to halt cancer growth in tough cases
NCT ID NCT06385496
Summary
This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced or hard-to-treat cancers that have specific genetic changes called mTOR mutations. The drug is designed to block a key enzyme that cancer cells need to grow. The goal is to see if the drug can shrink tumors or stop the cancer from progressing in patients who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.